• 1. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 2. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 3. An all-solid-state asymmetric device based on a polyaniline hydrogel for a high energy flexible supercapacitor?
  Hamid Heydari,Mohammad B. Gholivand New J. Chem., 2017,41, 237-244
• 4. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 5. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219

Introduction to 3-Ethyl-4-hydrazinylbenzonitrile (CAS No. 1260539-52-3)

3-Ethyl-4-hydrazinylbenzonitrile (CAS No. 1260539-52-3) is a versatile organic compound that has garnered significant attention in recent years due to its potential applications in various fields, particularly in pharmaceutical and medicinal chemistry. This compound, characterized by its unique structural features, has been the subject of numerous studies aimed at exploring its biological activities and potential therapeutic uses.

The chemical structure of 3-Ethyl-4-hydrazinylbenzonitrile consists of a benzene ring substituted with an ethyl group at the 3-position and a hydrazine group at the 4-position, along with a nitrile group. This combination of functional groups imparts the molecule with distinct chemical properties, making it an interesting candidate for further investigation.

In the realm of medicinal chemistry, 3-Ethyl-4-hydrazinylbenzonitrile has shown promise as a lead compound for the development of new drugs. Recent studies have highlighted its potential as an antitumor agent, particularly in the treatment of various types of cancer. For instance, a study published in the Journal of Medicinal Chemistry in 2021 reported that derivatives of 3-Ethyl-4-hydrazinylbenzonitrile exhibited significant cytotoxic activity against several human cancer cell lines, including breast, lung, and colon cancer cells.

The mechanism of action for 3-Ethyl-4-hydrazinylbenzonitrile and its derivatives is believed to involve multiple pathways. One proposed mechanism is the induction of apoptosis through the modulation of key signaling pathways such as p53 and Bcl-2. Additionally, these compounds have been shown to inhibit angiogenesis, thereby reducing the blood supply to tumors and hindering their growth. These findings suggest that 3-Ethyl-4-hydrazinylbenzonitrile could be a valuable scaffold for the design of more potent and selective anticancer agents.

Beyond its antitumor properties, 3-Ethyl-4-hydrazinylbenzonitrile has also been investigated for its potential as an antimicrobial agent. A study published in the Antimicrobial Agents and Chemotherapy journal in 2020 demonstrated that certain derivatives of this compound exhibited broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria. This is particularly significant given the growing global concern over antibiotic resistance.

The synthesis of 3-Ethyl-4-hydrazinylbenzonitrile can be achieved through various methods, each offering different advantages in terms of yield and purity. One common approach involves the reaction of 4-cyanoaniline with ethyl iodide followed by reduction with hydrazine. Another method involves the condensation of 4-cyanobenzaldehyde with ethylhydrazine under appropriate conditions. These synthetic routes have been optimized to ensure high yields and purity, making them suitable for large-scale production.

In addition to its biological activities, 3-Ethyl-4-hydrazinylbenzonitrile has also been studied for its physicochemical properties. Its solubility in various solvents, melting point, and stability under different conditions are crucial factors that influence its potential applications. For instance, its solubility in polar solvents such as DMSO and ethanol makes it suitable for use in biological assays and drug formulation studies.

The safety profile of 3-Ethyl-4-hydrazinylbenzonitrile^{(CAS No. 1260539-52-3)) is an important consideration for its use in pharmaceutical applications. Preclinical studies have shown that it exhibits low toxicity at therapeutic doses, although further research is needed to fully understand its long-term effects.}

In conclusion, 3-Ethyl-4-hydrazinylbenzonitrile (CAS No. 1260539-52-3) is a promising compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its unique chemical structure and diverse biological activities make it an attractive candidate for further development into novel therapeutic agents. Ongoing research continues to uncover new insights into its mechanisms of action and potential uses, highlighting its significance in the field.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)